Rein Therapeutics Inc. (NASDAQ:RNTX) Receives Average Rating of “Hold” from Analysts

Rein Therapeutics Inc. (NASDAQ:RNTX) has received an average recommendation of “Hold” from the four brokerages that are currently covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $6.00.

RNTX has been the topic of several analyst reports. HC Wainwright decreased their price target on shares of Rein Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Weiss Ratings lowered shares of Rein Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Wall Street Zen raised shares of Rein Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, June 6th. Finally, Maxim Group started coverage on Rein Therapeutics in a report on Monday, July 20th. They issued a “buy” rating and a $4.00 price target for the company.

Hedge Funds Weigh In On Rein Therapeutics

Large investors have recently added to or reduced their stakes in the business. Voss Capital LP grew its holdings in Rein Therapeutics by 59.2% in the 4th quarter. Voss Capital LP now owns 4,243,969 shares of the company’s stock valued at $4,923,000 after buying an additional 1,577,437 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Rein Therapeutics by 32.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,168,407 shares of the company’s stock worth $1,338,000 after acquiring an additional 284,300 shares during the period. Cable Car Capital LP acquired a new stake in shares of Rein Therapeutics in the second quarter worth approximately $588,000. Sigma Planning Corp boosted its position in shares of Rein Therapeutics by 41.0% in the first quarter. Sigma Planning Corp now owns 348,677 shares of the company’s stock worth $453,000 after acquiring an additional 101,400 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Rein Therapeutics by 15.1% in the fourth quarter. Geode Capital Management LLC now owns 284,555 shares of the company’s stock valued at $330,000 after purchasing an additional 37,244 shares during the period. 90.89% of the stock is currently owned by hedge funds and other institutional investors.

Rein Therapeutics Price Performance

Shares of NASDAQ:RNTX opened at $0.79 on Monday. Rein Therapeutics has a 52-week low of $0.76 and a 52-week high of $2.18. The stock’s fifty day simple moving average is $0.97 and its 200-day simple moving average is $1.18. The company has a market capitalization of $67.69 million, a P/E ratio of -0.42 and a beta of 1.35.

Rein Therapeutics (NASDAQ:RNTX) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.19) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.30. On average, sell-side analysts anticipate that Rein Therapeutics will post -0.53 earnings per share for the current year.

Rein Therapeutics Company Profile

Rein Therapeutics is a clinical-stage biotechnology company focused on developing novel immuno-oncology therapies for patients with solid tumors. The company’s core technology is a tumor-activated interleukin-12 (IL-12) prodrug platform, designed to confine cytokine activity to the tumor microenvironment and thereby enhance anti-tumor immunity while minimizing systemic toxicity.

The lead candidate, RT-101, is currently in early-phase clinical trials targeting multiple solid tumor indications, including head and neck cancer and non-small cell lung cancer.